A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Part of paid clinical trials in San Antonio, Texas.

Sponsor
Nutshell Therapeutics (Shanghai) Co., LTD.
Study ID
NCT07060989
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NTS071 — DRUG
    Oral administration

Study Details

This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

Key Dates

First listed
Jul 11, 2025
Start date
Aug 4, 2025
Status verified
Jun 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
220 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NTS071
    Single arm

Primary Outcome Measure

Phase 1: Number of dose-limiting toxicity (DLT) [ Time Frame: The first 26 days of treatment (Cycle 1) per patient ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Next OncologySan AntonioTexas78201-

Find similar trials in San Antonio, TX

By research site
Next Oncology· San Antonio, TX

Related Studies